𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Transforming growth factor β1 (TGF-β1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors

✍ Scribed by S. Jozan; M. Guerrin; P. Mazars; M. Dutaur; B. Monsarrat; F. Cheutin; R. Bugat; P. Martel; A. Valette

Publisher
John Wiley and Sons
Year
1992
Tongue
French
Weight
957 KB
Volume
52
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The effects of EGF and TGF‐β1 on the proliferation of 2 ovarian carcinoma cell lines (IGROV1 and OVCCR1) were evaluated. The cell lines were adapted to grow in a restricted serum (0.5%) medium. EGF was required for proliferation of both ovarian cell lines. Low doses of TGF‐β1 inhibited clonogenic capacity and attenuated the EGF‐mediated stimulation of DNA synthesis in OVCCR1 cells. TGF‐β1 inhibited OVCCR1 cell proliferation by blocking the cell cycle at the G~1~/S transition. TGF‐β1 did not affect either clonal or monolayer growth of IGROV1 cells. Both cell lines express type‐I and type‐III TGF‐β1 receptors, suggesting that the unresponsiveness of IGROV1 cells to TGF‐β1 occurs at a post‐receptor level. TGF‐β1 mRNA was detected in OVCCR1 cells and in 8 out of 11 of the ovarian tumor specimens examined. © 1992 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Multidrug transport in human glioblastom
Multidrug transport in human glioblastoma cells is inhibited by transforming growth factors type β1, β2, and β1.2
✍ Ph.D. H. J. Schluesener 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 1 views

The transforming growth factors type PI, p2, and p,.2 suppress multidrug transport in human pat-1 glioblastoma cells and even in cells that strongly overexpress mdr genes and are resistant to inhibition of multidrug transport by chemosensitizers. Thus, inhibition of multidrug transport by cytokines

Expression of transforming growth factor
Expression of transforming growth factor-beta (TGF-β) receptors, TGF-β1 and TGF-β2 production and autocrine growth control in osteosarcoma cells
✍ Peter Kloen; Candace L. Jennings; Mark C. Gebhardt; Dempsey S. Springfield; Henr 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 778 KB

Transforming growth factor-beta (TGF-P) is a polypeptide with multiple physiological functions. lsoforms of this growth factor have important roles in control of the cell cycle, in regulation of cell-cell interactions and in growth and development. Malignant transformation has been shown to be assoc

Transforming growth factors type β1 and
Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines
✍ Gerhard Zugmaier; Bruce W. Ennis; Bernd Deschauer; Deborah Katz; Cornelius Knabb 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 735 KB

At least one member of the TGF-P family, TGF-p1, has been previously shown to inhibit the anchorage-independent growth of some human breast cancer cell lines (Knabbe et al., 1487; Arteaga et al., 1988). Members of the TGF-P family might, [herefore, provide new strategies for breast cancer therapy. W

Expression of transforming-growth-factor
Expression of transforming-growth-factor (TGF)-β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-β1
✍ Ester Piek; Ulrica Westermark; Marianne Kastemar; Carl-Henrik Heldin; E. Joop va 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 268 KB 👁 1 views

A panel of 6 human glioma cell lines was examined for TGF-␤1 responsiveness. U-178 MG and U-251 MG AgCl1 were significantly inhibited by TGF-␤1, while U-343 MGa 31L and U-343 MGa 35L were potently stimulated to proliferate. TGF-␤1 induced endogenous PAI-1 protein synthesis, Smad binding element/(CAG